Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
Moon
Su-Jin
SJ
Department of Internal Medicine, The Catholic University of Korea, College of Medicine, 520-2 Daeheung-dong, Jung-gu, Daejeon, Korea.
Yoon
Hee-Jeoung
HJ
Her
Sung-Ho
SH
Lee
Jong-Min
JM
An
Ho-Jung
HJ
Lee
Yune-Jeong
YJ
Jin
Seung-Won
SW
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D002305:Cardiac Tamponade / Q000209:etiology* / Q000628:therapy; D004632:Emergency Medical Services; D006470:Hemorrhage / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D007723:Korea; D008297:Male; D020519:Pericardiocentesis; D010493:Pericarditis / Q000209:etiology* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab
Cardiology. 2007;107(3):172-7
16940721
Am J Ther. 2004 Jul-Aug;11(4):302-7
15266223
J Interv Cardiol. 2004 Apr;17(2):65-70
15104767
Circulation. 2004 May 11;109(18):2203-6
15117843
J Interv Cardiol. 2003 Oct;16(5):381-4
14603795